Published in Managed Care Business Week, March 7th, 2006
Researchers in the United States conducted a study "to evaluate the drug combination of discodermolide and taxol in human ovarian cancer cells and in an in vivo model of ovarian carcinoma. The combination index method was used to evaluate the interaction of taxol and discodermolide in human ovarian SKOV-3 carcinoma cells."
"Data were correlated with alterations in cell cycle distribution and caspase activation. In addition, SKOV-3 xenograft-bearing mice were treated with either taxol, discodermolide, or a combination of both drugs given concurrently to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week